A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients - Concepedia

Concepedia

Publication | Open Access

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients

DOI Full Paper Access

162

Citations

27

References

2013

Year

Brandon W. Higgs, Wei Zhu, Chris Morehouse, Wendy I. White, Philip Z. Brohawn, Xiang Guo, Marlon C. Rebelatto, Chenxiong Le, Anthony A. Amato, David Fiorentino,

Annals of the Rheumatic Diseases

References

	Year	Citations

Page 1